Morgan Stanley Maintains Equal-Weight on Kymera Therapeutics, Lowers Price Target to $66
Morgan Stanley maintains Kymera Therapeutics (NASDAQ:KYMR) with a Equal-Weight and lowers the price target from $68 to $66.
Wells Fargo Initiates Coverage On Kymera Therapeutics with Overweight Rating, Announces Price Target of $62
Wells Fargo analyst Derek Archila initiates coverage on Kymera Therapeutics (NASDAQ:KYMR) with a Overweight rating and announces Price Target of $62.
48 Biggest Movers From Yesterday
Gainers
Singularity Future Technology Ltd. (NASDAQ: SGLY) shares rose 25.9% to settle at $5.01 on Thursday.
MedAvail Holdings, Inc (NASDAQ: MDVL) gained 24.4% to settle at $1.58.
Kymera Announced Multiple Ascending Dose (Mad) Data From Kt-474 Phase 1 Trial Demonstrates Near Complete Irak4 Degradation in Pbmc and Skin, Robust Ex Vivo Inhibition of Multiple Disease-relevant Cytokines, and Favorable Safety Profile
Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today announced significant advances across its clinical stage pipeline, new programs and platform investments at its first R&D Day.
Kymera Therapeutics Presents Preclinical Data On Selective STAT3 Degraders For Hematological And Solid Tumor Malignancies At 63rd American Society Of Hematology Annual Meeting
Kymera Therapeutics, Inc. (NASDAQ:KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel, small molecule protein degrader therapeutics, today announced the company presented new
Kymera Therapeutics To Present New Preclinical Data On STAT3 Degraders At The Society For Immunotherapy Of Cancer’s 36th Annual Meeting And The 63rd American Society Of Hematology Annual Meeting
Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today announced that the
Kymera Therapeutics to Present Pharmacokinetic and Pharmacodynamic Data, including Cytokines, from the Single Ascending Dose Portion of KT-474 Phase 1 Trial in Healthy Volunteers at the 4th Annual Targeted Protein Degradation Summit
Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today announced that the
Where Kymera Therapeutics Stands With Analysts
Over the past 3 months, 5 analysts have published their opinion on Kymera Therapeutics (NASDAQ:KYMR) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
